EGFR and colorectal carcinoma: Although the CRC molecular heterogeneity led to partially distinct mechanisms of cooperation between NEDD8 and EGFR pathway blockade, the observed preclinical results warrant further investigations to better identify patients that could benefit from the various possible versions of the combined blockade.